Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment

Multiple Cancer Types

This is a two-part study of NUC-3373 administered every 2 weeks as an intravenous infusion, in separate combinations with leucovorin, oxaliplatin, oxaliplatin + bevacizumab, oxaliplatin + panitumumab, irinotecan, and irinotecan + cetuximab. The primary objective is to identify a recommended dose for NUC-3373 when combined with these agents.
Colon, Phase I, Rectal
I
Ciombor, Kristen
NCT03428958
VICCGIP1851

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: